Follicum Details Clinical Progress Of Hair Growth Stimulating Product

A side effect observed during preclinical studies of a potential heart drug is underpinning the development of a peptide that shows promise in restoring hair growth. Follicum AB CBO Gunnar Gårdemyr took time out during his busy partnering schedule at BIO-Europe Spring 2018 to update Scrip on the progress the company is making with FOL-005, which is currently in Phase I/II studies and available for out-licensing.

Gunnar Gardemyr
Gunnar Gårdemyr, CBO of Follicum AB • Source: Lucie Ellis

A side effect observed during preclinical studies of a potential heart drug is underpinning the development of a peptide that shows promise in restoring hair growth. Follicum AB CBO Gunnar Gårdemyr took time out during his busy partnering schedule at BIO-Europe Spring 2018 to update Scrip on the progress the company is making with FOL-005, which is currently in Phase I/II studies and available for out-licensing.

Open

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Quick Listen: Scrip’s Five Must-Know Things

 
• By 

In this week's episode: AstraZeneca CEO cautions Europe; Pfizer CEO optimistic on US tariffs, pricing; Merck & Co reassures on pipeline; Merck KGaA buys SpringWorks; and Akeso explains ivonescimab overall survival data.

Vertex Sinks On Below-Consensus Revenue, Limited Sales From New Launches

 
• By 

Vertex is in need of diversification, but in addition to its lower-than-expected Q1 revenue, sales of the company’s newest CF drug Alyftrek and pain medicine Journavx disappointed.

Aldeyra Plans To File Reproxalap Again With New Dry Eye Symptom Data

 
• By 

The biotech hopes a third time will be the charm after two FDA complete responses, with plans to position its eye drop as offering quicker onset of action.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

More from Scrip

Atara Does An About Face As FDA Lifts Ebvallo Hold

 

The biotech said it will have a type A meeting with the agency to resubmit for the cell therapy’s approval in EBV+ PTLD.

Lilly And Alchemab Tap Into Resilient Individuals To Develop ALS Drug

 

The pharma company is helping to validate the biotech’s model by developing a novel amyotrophic lateral sclerosis candidate, based on its novel approach that ‘turns drug discovery on its head’.

Switzerland Biopharma To Stay Strong Despite More Cash Going To US And China

 
• By 

The sector is continuing to show resilience despite financial and market challenges.